To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer

Inclusion Criteria: 1. Age ≥18, ≤70 years old; 2. Cervical cancer patients diagnosed by histopathology; 3. Need to receive multi-cycle radical concurrent radiochemotherapy; 4. FN risk \> 20% if rhG-CSF was not accepted; High risk factors associated with FN and planed to use the same protocol in subsequent cycles(docetaxel+cisplatin regimen)； 5. Performance status score(KPS)≥70; 6. No obvious blood system disease,absolute neutrophil count（ANC）≥ 1.5×10\^9/L, platelet count≥80×10\^9 /L, hemoglobin（Hb）≥75 g/L, and no bleeding tendency; 7. The patient signs the informed consent. Exclusion Criteria: 1. With infection difficult to control, or received system antibiotic treatment within 72 h before chemotherapy; 2. Any bone marrow abnormalities and other hematopoietic ; 3. Had received bone marrow or hematopoietic stem cell transplantation within 3 months; 4. with other malignancies not cure, or with brain metastases; 5. Liver function tests:total bilirubin(TBIL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were all ≥2.5 times normal upper limit. 6. Renal function tests: serum creatinine (Cr)\> 1.5 times normal upper limit; 7. Allergic to the drugs or other genetic engineering biological products from Escherichia coli; 8. Suffering from mental or neurological disorders; 9. Investigator think it is not suitable for recruiting.